title: Adrenocorticotropin causes vasodilatation in the human fetal-placental circulation.
abstract: During human pregnancy, ACTH is produced by both the placenta and fetal pituitary. ACTH has been shown to cause vasodilatation in the adrenal cortex in vitro. In this context we have investigated the vasoactive effects of ACTH in the human fetal-placental circulation. Single lobules of term human placentas were bilaterally perfused in vitro with Krebs solution (maternal and fetal, 5 mL/min; 95% O2-5% CO2; 37 C; pH 7.3), and changes in fetal placental arterial perfusion pressure (FAP) were measured. ACTH (40-4000 pmol/L; n = 5) caused a dose-dependent reduction of both KC1 and PGF2alpha-induced increases in FAP in the fetal placental circulation. The reductions were of a similar magnitude in the presence of either constrictor agent. ACTH was 187.4 (95% confidence limits, 162.7-215.9) times more potent than prostacyclin (PGI2; 1.2-1180 nmol/L; n = 6), which is a known vasodilator of the fetal-placental circulation. The threshold concentrations for ACTH and PGI2 were 40 pmol/L and 1.2 nmol/L, respectively. ACTH-induced reductions in PGF2alpha-induced increases in FAP in the fetal placental circulation were not inhibited by the nitric oxide synthase inhibitor, N omega-nitro-L-arginine (100 micromol/L; n = 5), the cyclooxygenase inhibitor indomethacin (3 micromol/L; n = 5), or a guanylate cyclase inhibitor LY83583(1 micromol/L; n = 5). The inhibitory effect of ACTH was attenuated by the antagonist, ACTH-(7-38) (240 pmol/L; n = 4), and a polyclonal ACTH antiserum (1:1000 dilution; n = 4). We have demonstrated that ACTH causes a reduction in fetal placental vascular resistance in the human fetal-placental circulation in vitro. The mechanism by which it exerts these effects has not been defined, but neither nitric oxide nor PG-mediated pathways appear to be involved.
authors.affiliation: Department of Endocrinology, John Hunter Hospital, Newcastle, South Wales, Australia.
authors.forename: V L
authors.initials: VL
authors.lastname: Clifton
authors.forename: M A
authors.initials: MA
authors.lastname: Read
authors.forename: A L
authors.initials: AL
authors.lastname: Boura
authors.forename: P J
authors.initials: PJ
authors.lastname: Robinson
authors.forename: R
authors.initials: R
authors.lastname: Smith
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000494:pharmacology*; D000328:Adult; D000704:Analysis of Variance; D001794:Blood Pressure / Q000187:drug effects; D015237:Dinoprost / Q000494:pharmacology; D011464:Epoprostenol / Q000494:pharmacology; D005260:Female; D005333:Fetus; D006801:Humans; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D008431:Maternal-Fetal Exchange / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology; D010446:Peptide Fragments / Q000494:pharmacology; D010920:Placenta; D011247:Pregnancy; D014469:Umbilical Arteries / Q000187:drug effects / Q000502:physiology*; D014471:Umbilical Veins / Q000187:drug effects / Q000502:physiology*; D014655:Vascular Resistance / Q000187:drug effects; D014664:Vasodilation; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D010446:Peptide Fragments; D014665:Vasodilator Agents; C026034:ACTH (7-38); D000324:Adrenocorticotropic Hormone; D015237:Dinoprost; D011464:Epoprostenol; D007213:Indomethacin